UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

Journal of cystic fibrosis, 2022-07, Vol.21 (4), p.574-580

2022

Volltextzugriff (PDF)

C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response

Journal of cystic fibrosis, 2022-07, Vol.21 (4), p.588-593

2022

Volltextzugriff (PDF)

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Journal of cystic fibrosis, 2020-09, Vol.19 (5), p.677-687

2020

Volltextzugriff (PDF)

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

Journal of cystic fibrosis, 2016-11, Vol.15 (6), p.783-790

2016

Volltextzugriff (PDF)

Antipseudomonal treatment decisions during CF exacerbation management

Journal of cystic fibrosis, 2022-09, Vol.21 (5), p.753-758

2022

Volltextzugriff (PDF)

Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment

Journal of cystic fibrosis, 2021-01, Vol.20 (1), p.36-38

2021

Volltextzugriff (PDF)

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Journal of cystic fibrosis, 2017-09, Vol.16 (5), p.607-615

2017

Volltextzugriff (PDF)

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study

Journal of cystic fibrosis, 2015-09, Vol.14 (5), p.632-638

2015

Volltextzugriff (PDF)

Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States

Journal of cystic fibrosis, 2023-05, Vol.22 (3), p.456-463

2023

Volltextzugriff (PDF)

WS23.4 IV antibiotic treatment of <9 days and treatment at home for CF pulmonary exacerbation are associated with increased odds of IV retreatment within 30 days

Journal of cystic fibrosis, 2016-06, Vol.15, p.S35-S35

2016

Volltextzugriff (PDF)

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

The New England journal of medicine, 2015-07, Vol.373 (3), p.220-231

2015

Volltextzugriff (PDF)

138 Impact of pulmonary exacerbations (PEx) on health-related quality of life (HRQoL) assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) in TRAFFIC and TRANSPORT

Journal of cystic fibrosis, 2016-06, Vol.15, p.S86-S86

2016

Volltextzugriff (PDF)

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

Journal of cystic fibrosis, 2016-06, Vol.15, p.S60-S61

2016

Volltextzugriff (PDF)

115 Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis – Cochrane review

Journal of cystic fibrosis, 2015-06, Vol.14, p.S86-S86

2015

Volltextzugriff (PDF)

Adults with cystic fibrosis in Portugal: A first step towards improvement

Revista portuguesa de pneumologia (English ed.), 2016-05, Vol.22 (3), p.139-140

2016

Volltextzugriff (PDF)

38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin

Journal of cystic fibrosis, 2016-06, Vol.15, p.S61-S61

2016

Volltextzugriff (PDF)

117 Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis clinical trials

Journal of cystic fibrosis, 2015-06, Vol.14, p.S87-S87

2015

Volltextzugriff (PDF)

5 Nontuberculous mycobacterial infection as a barrier to lung transplantation in people with cystic fibrosis

Journal of cystic fibrosis, 2023-10, Vol.22, p.S3-S4

2023

Volltextzugriff (PDF)

189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response

Journal of cystic fibrosis, 2015-06, Vol.14, p.S106-S106

2015

Volltextzugriff (PDF)

188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations

Journal of cystic fibrosis, 2015-06, Vol.14, p.S106-S106

2015

Volltextzugriff (PDF)

WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations

Journal of cystic fibrosis, 2015-06, Vol.14, p.S13-S13

2015

Volltextzugriff (PDF)

512 Patient perceptions of mental health adverse effects from elexacaftor/tezacaftor/ivacaftor in a pediatric and adult CF center

Journal of cystic fibrosis, 2024-09, Vol.23, p.S279-S279

2024

Volltextzugriff (PDF)

WS02.3 Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD)

Journal of cystic fibrosis, 2015-06, Vol.14, p.S3-S3

2015

Volltextzugriff (PDF)

58 Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor

Journal of cystic fibrosis, 2013-06, Vol.12, p.S63-S63

2013

Volltextzugriff (PDF)

718 Rates of longitudinal estimated glomerular filtration rate decline in participants in the Standardized Treatment of Pulmonary Exacerbations clinical trial

Journal of cystic fibrosis, 2024-09, Vol.23, p.S406-S406

2024

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(130)

Publikationsform

Artikel
(141)
Berichte
(1)

Sprache

Englisch
(142)

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Humans
(60)
Life Sciences & Biomedicine
(60)
Respiratory System
(44)
Cystic Fibrosis
(36)
Female
(33)
Biological And Medical Sciences
(32)
Adult
(31)
Medical Sciences
(31)
Male
(29)
Pulmonary/respiratory
(26)
General & Internal Medicine
(23)
Critical Care Medicine
(19)
Cystic Fibrosis - Complications
(15)
Cystic Fibrosis - Drug Therapy
(15)
Cystic Fibrosis - Therapy
(14)
Adolescent
(13)
Child
(12)
Middle Aged
(12)
Anti-Bacterial Agents - Therapeutic Use
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

Antipseudomonal treatment decisions during CF exacerbation management

Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study

Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States

WS23.4 IV antibiotic treatment of <9 days and treatment at home for CF pulmonary exacerbation are associated with increased odds of IV retreatment within 30 days

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

138 Impact of pulmonary exacerbations (PEx) on health-related quality of life (HRQoL) assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) in TRAFFIC and TRANSPORT

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

115 Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis – Cochrane review

Adults with cystic fibrosis in Portugal: A first step towards improvement

38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin

117 Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis clinical trials

5 Nontuberculous mycobacterial infection as a barrier to lung transplantation in people with cystic fibrosis

189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response

188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations

WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations

512 Patient perceptions of mental health adverse effects from elexacaftor/tezacaftor/ivacaftor in a pediatric and adult CF center

WS02.3 Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD)

58 Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor

718 Rates of longitudinal estimated glomerular filtration rate decline in participants in the Standardized Treatment of Pulmonary Exacerbations clinical trial

Suchergebnisse filtern